|
タカダ タクマ
TAKADA Takuma
髙田 卓磨 所属 研究施設 研究施設 職種 助教 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial. |
| 掲載誌名 | 正式名：Circulation journal : official journal of the Japanese Circulation Society 略 称：Circ J ISSNコード：13474820/13469843 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.Online ahead of print. |
| 著者・共著者 | Chatani Ryuki, Yamashita Yugo, Morimoto Takeshi, Muraoka Nao, Shioyama Wataru, Shibata Tatsuhiro, Nishimoto Yuji, Ogihara Yoshito, Doi Kosuke, Oi Maki, Shiga Taro, Sueta Daisuke, Kim Kitae, Tanabe Yasuhiro, Koitabashi Norimichi, Takada Takuma, Ikeda Satoshi, Nakagawa Hitoshi, Mitsuhashi Takayuki, Shoji Masaaki, Sakamoto Jiro, Hisatake Shinji, Ogino Yutaka, Fujita Masashi, Nakanishi Naohiko, Dohke Tomohiro, Hiramori Seiichi, Nawada Ryuzo, Kaneda Kazuhisa, Mushiake Kazunori, Yamamoto Hiromi, Kadota Kazushige, Ono Koh, Kimura Takeshi, |
| 発行年月 | 2024/03 |
| 概要 | BACKGROUND:Patients with appropriately selected low-risk pulmonary embolism (PE) can be treated at home, although it has been controversial whether applies to patients with cancer, who are considered not to be at low risk.Methods and Results: The current predetermined companion report from the ONCO PE trial evaluated the 3-month clinical outcomes of patients with home treatment and those with in-hospital treatment. The ONCO PE trial was a multicenter, randomized clinical trial among 32 institutions in Japan investigating the optimal duration of rivaroxaban treatment in cancer-associated PE patients with a score of 1 using the simplified version of the Pulmonary Embolism Severity Index (sPESI). Among 178 study patients, there were 66 (37%) in the home treatment group and 112 (63%) in the in-hospital treatment group. The primary endpoint of a composite of PE-related death, recurrent venous thromboembolism (VTE) and major bleeding occurred in 3 patients (4.6% [0.0-9.6%]) in the home treatment group and in 2 patients (1.8% [0.0-4.3%]) in the in-hospital treatment group. In the home treatment group, there were no cases of PE-related death or recurrent VTE, but major bleeding occurred in 3 patients (4.6% [0.0-9.6%]), and 2 patients (3.0% [0.0-7.2%]) required hospitalization due to bleeding events.CONCLUSIONS:Active cancer patients with PE of sPESI score=1 could be potential candidates for home treatment. |
| DOI | 10.1253/circj.CJ-24-0004 |
| PMID | 38462535 |